From the Journals

10% with diabetes hospitalized for COVID-19 die within a week


 

Analysis ongoing, ‘some new messages might pop up’

After adjustment for age and sex, BMI was significantly and positively associated with the primary outcome (P = .0001) but not with death on day 7 (P = .1488), and A1c wasn’t associated with either outcome.

In a multivariable analysis that included characteristics prior to admission, BMI remained the only independent preadmission predictor associated with the primary outcome (adjusted odds ratio, 1.28), while factors independently associated with risk of death on day 7 included age, diabetes complication history, and treated obstructive sleep apnea.

And after adjustment for age and sex, admission plasma glucose level was significantly and positively associated with both the primary outcome (P = .0001) and death on day 7 (P = .0059).

In the multivariate analysis, admission characteristics that predicted the primary outcome were dyspnea, lymphopenia, increased AST, and increased C-reactive protein.

Dr. Hadjadj said his team is now “focusing on specific risk factors such as obesity, age, vascular complications, medications ... to perform some deeper analyses.”

“We look forward to analyzing the data on in-hospital stay up to day 28 after admission. Some new messages might well pop up,” he added.

But in the meantime, “Elderly populations with long-term diabetes with advanced diabetes-related complications and/or treated obstructive sleep apnea were particularly at risk of early death and might require specific management to avoid infection with the novel coronavirus,” the researchers stressed.

The study received funding from the Fondation Francophone de Recherche sur le Diabète and was supported by Novo Nordisk, MSD, Abbott, AstraZeneca, Lilly, and the Fédération Française des Diabétiques; Société Francophone du Diabète; and Air Liquide Healthcare International. Dr. Hadjadj reported receiving grants, personal fees, and/or nonfinancial support from AstraZeneca, Bayer, Boehringer Ingelheim, Dinno Santé, Eli Lilly, LVL, MSD, Novartis, Pierre Fabre Santé, Sanofi, Servier, and Valbiotis.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

FDA approves dapagliflozin for low-EF heart failure
MDedge Endocrinology
More guidance on inpatient management of blood glucose in COVID-19
MDedge Endocrinology
Adolescent obesity, diabetes linked to atherosclerotic signs
MDedge Endocrinology
Health care costs nearly doubled for patients with NAFLD
MDedge Endocrinology
Glucose control linked to COVID-19 outcomes in largest-yet study
MDedge Endocrinology
ARBs didn't raise suicide risk in large VA study
MDedge Endocrinology
Seek safe strategies to diagnose gestational diabetes during pandemic
MDedge Endocrinology
Medicare will offer a $35/month insulin-cost cap in 2021
MDedge Endocrinology
‘The story unfolding is worrisome’ for diabetes and COVID-19
MDedge Endocrinology
FDA recalls extended-release metformin due to NDMA impurities
MDedge Endocrinology